NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

HyGro,

Oncologists have always attempted to measure and predict PFS. They always should try, and they always will try to measure progression and predict survival. Predicting survival in advance of death is always worthwhile.

OS is the ultimate standard, but you cannot wait until death to begin evaluating whether a cancer drug is efficacious. The physician must evaluate a patient’s response and try to determine whether the treatment is helping.

Today, doctors have better methods for measuring progression, particularly when studying immunotherapy agents which are still relatively new as the emerging field of cell-based science is leading to rapid changes in the understanding of how cancer can be assessed and treated.

The P3 for the DCVax-L cell-based technology spanned many years. If the trial were designed and commenced in 2023, the investigators would appropriately attempt to measure progression and predict survival using the best methods and most current medical knowledge available in 2023, as any cancer researcher would.

https://brownneurosurgery.com/breakthrough-brain-cancer-vaccine/